Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW BRUNSWICK, N.J., Dec. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) supporting the use of the Johnson & Johnson COVID-19 vaccine as a booster shot in persons aged 18 years and above.

World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster

NEW BRUNSWICK, N.J., Dec. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the appointment of several senior leaders to the Company's Executive Committee.

Johnson & Johnson Appoints Senior Leaders to Executive Committee

Johnson & Johnson (JNJ) closed at $163.36 in the latest trading session, marking a +0.26% move from the prior day.

Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced additional vaccine efficacy and safety data from its Phase 2b CYPRESS study of its respiratory syncytial virus (RSV) adult vaccine candidate.  J&J shared top-line findings from the Phase 2b trial, revealing it hit its primary endpoint by linking the vaccine to 80% efficacy against confirmed RSV-associated lower respiratory tract disease.

Johnson & Johnson Posts Additional RSV Vaccine Data

Coca-Cola

Palo Alto Networks

Stanley Black & Decker

Texas Instruments

Verizon

WBI Power Factor High Dividend ETF

Despite uncertainty around the impact of the Omicron variant, these seven cheap stocks look promising heading into the new year. The post 7 Stocks to Watch as the Omicron Variant Becomes the Market's New Wildcard appeared first on InvestorPlace.

7 Stocks to Watch as the Omicron Variant Becomes the Market's New Wildcard

BioNTech SE

Moderna

Novavax

Pfizer

Big declines show the uncertainty investors have about the future of fighting COVID-19.

Vaccine Stocks: The Beginning of the End?

Booster dose of J&J's (JNJ) COVID-19 vaccine elicits comparable neutralizing activity and higher T-cell responses in previously-vaccinated persons with Comirnaty.

J&J (JNJ) COVID-19 Booster Jab Compares Well With Comirnaty

Johnson & Johnson (NYSE: JNJ) announced preliminary results from an independent study, including a subset of the Janssen-sponsored COV2008 study participants. The article describing these results has been posted on  medRxiv.

Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab

Cisco Systems

Goldman Sachs

Microsoft

Procter & Gamble

Here are the long-short recommendations for this month.

Stocks To Trade In December

NEW BRUNSWICK, N.J., Dec. 5, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D.

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

The shares of Johnson & Johnson (NYSE: JNJ) have received a price target of $200 from Credit Suisse. These are the details.

Johnson & Johnson Stock (JNJ): $200 Price Target Reiterated By Credit Suisse

Novartis

Eighteen large U.S. and European drug companies will have more than $1.7 trillion in buying power by the end of 2022, according to SVB Leerink analyst Geoffrey Porges. That includes $500 billion in cash, which the companies can use for mergers and acquisitions, to pay down debt or reward shareholders via dividends or share buybacks, the Leerink analyst said.

J&J, Pfizer, Novartis Among Pharma Giants With Biggest War Chests

Apple

Caterpillar

Celsius Holdings

Dow Inc

Enphase Energy

Himax Tech

Intel

Intrepid Potash

McDonald's

Trillium Therapeutics

Walmart

Two sample Breakout Stocks for Week 49 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. This past week 2 stocks beat 10% peak gains with VIR +39.9% and GRTS +26.5% despite very high negative Momentum Gauge® signals and large market declines.

Week 49 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

Bristol-Myers

Could Bristol Myers Squibb and Johnson & Johnson Have a Powerful New Blood Thinner on the Way?

RARITAN, N.J., Dec. 3, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) today announced it will present data from six company-sponsored studies in support of their respiratory syncytial virus (RSV) adult vaccine candidate at the Eighth European Scientific Working Group on Influenza (ESWI) meeting.

Janssen to Showcase Progress on Respiratory Syncytial Virus (RSV) Vaccine Candidate at ESWI 2021

Regeneron Pharmaceuticals

The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.

COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron

Merck

Vir Biotechnology

Could biotech stocks be top buys as the world battles a new Covid-19 variant?

5 Biotech Stocks For Your December 2021 Watchlist

AbbVie

Abbott Labs

Medtronic

Walgreens

Just when you thought it was starting to look safer, yet another COVID-19 variant comes around.

5 Health Care Dividend Aristocrats to Buy for 2022 as Yields Plunge Once Again

J&J (JNJ) is testing the blood serum from participants of completed and ongoing booster studies for neutralizing activity against the Omicron variant

J&J (JNJ) to Explore Omicron Version of its COVID Vaccine

The omicron variant dealt the stock market a blow, but these vaccine stocks promise investors a way to cash in while combatting Covid-19. The post 5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market appeared first on InvestorPlace.

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

One of the oldest American companies JNJ was incorporated in 1886 and has been a health care leader throughout its history, annually increasing its dividend for 59 years. Its present plan to split into two companies spins off the consumer division (16% of sales) to focus on higher growth pharmaceutical and medical device areas.

Is Johnson & Johnson Split Into Two Companies Good For Stock Investors?

AstraZeneca

Fears about the Omicron variant of Covid-19 rattled the world's financial markets Friday and early Monday morning. But shares of the major coronavirus vaccine makers were getting a boost from the latest pandemic jitters.

News for Johnson & Johnson Stock (JNJ)